J&J Buys Pfizer Consumer Division For $16.6 Bil.
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson CEO William Weldon says the deal will make the firm's portfolio "more balanced," with 40% devoted to pharmaceuticals, 35% to medical devices and 25% to consumer products.
You may also be interested in...
Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?
A mega merger combining Pfizer and Wyeth would create a behemoth with combined sales of over $70 billion, build Pfizer's experience base in biotech, give Pfizer the substantial vaccine business it has been searching for and create billions in cost savings opportunities
Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?
A mega merger combining Pfizer and Wyeth would create a behemoth with combined sales of over $70 billion, build Pfizer's experience base in biotech, give Pfizer the substantial vaccine business it has been searching for and create billions in cost savings opportunities
Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?
Combination of Pfizer and Wyeth would create a drug powerhouse with combined sales of over $70 billion, strengthen Pfizer’s position in biotech and vaccines and create billions in cost savings opportunities.